C12N 2740/15062
By genetic engineering
Official title: by genetic engineering
C12N2740/15062 (By genetic engineering) appears on 4 US grants and 11 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 11
- Assignees
- 9
- Inventors
- 37
- Latest grant
- 22 Jul 2014
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 2 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 2 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 3 |
| 2023 | 0 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- HIV DNA vaccine methods of use22 Jul 2014US 8,785,411 B2University of Kansas Medical Center
- DNA vaccine compositions with HIV/SIV gene modifications1 Jul 2014US 8,765,140 B2University of Kansas Medical Center
- Attenuated lentivirus vectors expressing interferon4 Dec 2001US 6,326,007 B1The Regents of the University of California
- Equine infectious anemia virus vectors6 Nov 2001US 6,312,683 B1Oxford Biomedica (UK) Limited
- Lentiviral vector17 Apr 2025US 2025/0122528 A1Touchlight IP Limited
- Retargeted retroviral vectors resistant to vaccine-induced neutralization and compositions or methods of use thereof19 Sep 2024US 2024/0307555 A1The Broad Institute, Inc.
- Retargeted retroviral vectors and compositions or methods of use thereof5 Sep 2024US 2024/0294942 A1The Broad Institute, Inc.
- Lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses in a host16 Nov 2023US 2023/0364216 A1
- Enhancing Production of Lentiviral Vectors3 Nov 2022US 2022/0348958 A1Oxford Biomedica (UK) Limited
Most cited
By later US patents